February 2013 Edition Vol.7, Issue 2
Just two years ago, 60% of oncologists preferred prescribing an IV drug over a therapeutically equivalent oral option; however, in 2012, just over 50% of oncologists preferred prescribing an IV drug regimen.4 In a 2012 Kantar Health Oncology Market Access survey (N=150), among oncologists who responded, they indicated they are more likely to prescribe an oral versus an IV drug because of increased convenience for patients and the support they receive with administrative, financial and clinical management issues from a specialty pharmacy.5
For payers, improved specialty pharmaceutical care not only supports patient outcomes, it also reduces unnecessary spend due to incorrect dosing, and emergency department visits to resolve drug-drug interactions or difficult-to-tolerate side effects. Payers may also use a specialty pharmacy to check a patient’s biomarker status, which ensures what patients are qualified to receive biomarker-targeted drugs (Figure 3). Pfizer uses five specialty pharmacies to support Xalkori for ALK-positive non-small cell lung cancer.
Source: Kantar Health Managed Care Organization Survey, August 2012 and April 2011
(continued on page 2)